Concizumab-mtci (Alhemo) prophylaxis for hemophilia A and B
Customize your policy alerts
Sign up for Health Net Policy CP.PHAR.625 alerts
Get alerted when Policy CP.PHAR.625 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization criteria for Alhemo (concizumab-mtci) when used for routine prophylaxis to prevent or reduce bleeding in patients ≥12 years with hemophilia A or B, with or without inhibitors. Applies to Health Net lines of business listed in the policy.
HCPCS code J7173 (Injection, concizumab-mtci, 0.5 mg) was added to the policy.
Requirements for documentation and provider attestations of Concizumab ELISA were removed.
Initial and continued approval durations were modified for Medicaid/HIM and Commercial lines of business.
New indication added for hemophilia A and B without inhibitors.
Provider confirmation of discontinuation of prophylactic hemophilia agents changed to an exclusion for concurrent use, with examples for on-demand use.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.